Sidoti Equities Analysts Raise Earnings Estimates for Cibus

Cibus, Inc. (NASDAQ:CBUS) – Analysts at Sidoti boosted their Q2 2026 EPS estimates for shares of Cibus in a research report issued on Friday, May 15th. Sidoti analyst A. Hantman now forecasts that the company will earn ($0.35) per share for the quarter, up from their prior estimate of ($0.36). The consensus estimate for Cibus’ current full-year earnings is ($1.26) per share. Sidoti also issued estimates for Cibus’ Q3 2026 earnings at ($0.35) EPS, Q4 2026 earnings at ($0.28) EPS, FY2026 earnings at ($1.31) EPS, Q1 2027 earnings at ($0.27) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.24) EPS, Q4 2027 earnings at ($0.25) EPS and FY2027 earnings at ($1.02) EPS.

A number of other analysts have also weighed in on CBUS. Jefferies Financial Group upped their target price on shares of Cibus from $1.90 to $3.00 and gave the stock a “hold” rating in a report on Wednesday, March 25th. Weiss Ratings reissued a “sell (e+)” rating on shares of Cibus in a research note on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Cibus presently has an average rating of “Hold” and an average price target of $9.00.

Cibus Trading Down 2.3%

Cibus stock opened at $1.28 on Tuesday. The firm’s 50 day simple moving average is $2.04 and its 200 day simple moving average is $1.97. The firm has a market capitalization of $97.70 million, a PE ratio of -0.65 and a beta of 1.66. Cibus has a 1-year low of $1.09 and a 1-year high of $4.19.

Cibus (NASDAQ:CBUS) last posted its earnings results on Thursday, May 14th. The company reported ($0.33) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.06). The firm had revenue of $1.68 million for the quarter, compared to the consensus estimate of $1.61 million. Cibus had a negative return on equity of 200.87% and a negative net margin of 2,366.33%.

Institutional Investors Weigh In On Cibus

A number of institutional investors have recently made changes to their positions in the business. Weiss Asset Management LP purchased a new stake in shares of Cibus in the 1st quarter valued at $1,758,000. OMERS ADMINISTRATION Corp purchased a new stake in shares of Cibus in the 1st quarter valued at $66,000. Renaissance Technologies LLC boosted its stake in shares of Cibus by 42.5% in the 1st quarter. Renaissance Technologies LLC now owns 98,900 shares of the company’s stock valued at $196,000 after purchasing an additional 29,500 shares in the last quarter. Dimensional Fund Advisors LP purchased a new stake in shares of Cibus in the 1st quarter valued at $33,000. Finally, Corient Private Wealth LLC purchased a new stake in shares of Cibus in the 4th quarter valued at $145,000. Hedge funds and other institutional investors own 33.81% of the company’s stock.

Key Cibus News

Here are the key news stories impacting Cibus this week:

• Positive Sentiment: Sidoti raised earnings estimates for several upcoming quarters, including Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, and Q4 2027, suggesting a modestly better outlook for Cibus’ loss trajectory. Cibus analyst estimate update
• Positive Sentiment: Sidoti also improved its FY2027 EPS forecast for Cibus, indicating analysts see some longer-term improvement in profitability. Cibus FY2027 estimate update
• Neutral Sentiment: HC Wainwright slightly adjusted some longer-range estimates, with mixed changes across FY2026, FY2027, FY2028, and FY2029, which does not materially change the near-term investment case. Cibus HC Wainwright estimate update
• Negative Sentiment: Despite the analyst revisions, Cibus is still expected to post significant losses in the coming years, with full-year 2026 EPS consensus at -$1.26 and FY2027 still projected to be negative at about -$1.02, reinforcing concerns about profitability. Cibus profitability outlook

About Cibus

Cibus, Inc is a biotechnology company specializing in precision gene editing for agricultural applications. Leveraging its proprietary Rapid Trait Development System (RTDS), Cibus develops improved crop traits without the introduction of foreign DNA. The company’s platform enables targeted modifications to plant genomes, allowing for enhanced disease resistance, herbicide tolerance and yield optimization in key row crops.

The company’s core business centers on trait development services and licensing partnerships.